July 2024 Provider Newsletter

Contents

AdministrativeCommercialJuly 1, 2024

Anesthesia modifiers — professional editing update

AdministrativeCommercialJuly 1, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Drugs and biologic

AdministrativeCommercialMedicare AdvantageMedicaid Managed CareJune 18, 2024

Phoenix Sepsis Criteria for coding and billing pediatric sepsis

AdministrativeCommercialJuly 1, 2024

CAA: Maintain your online provider directory information

AdministrativeMedicaid Managed CareJanuary 1, 2024

New resources available for ePRAF

AdministrativeMedicaid Managed CareJuly 1, 2024

Anatomical modifiers

Education & TrainingCommercialJune 13, 2024

Faster notification of EDI corrected claims errors

Education & TrainingCommercialMedicare AdvantageMedicaid Managed CareJuly 1, 2024

July is Disability Awareness Month

Education & TrainingMedicaid Managed CareJuly 1, 2024

Access instant health plan information via Availity Essentials

Education & TrainingMedicaid Managed CareJuly 1, 2024

Join our Provider Advisory Council

Education & TrainingMedicaid Managed CareJuly 1, 2024

You are invited: Behavioral health provider orientation

Education & TrainingMedicaid Managed CareJuly 1, 2024

You are invited: Provider orientation

Education & TrainingMedicaid Managed CareJuly 1, 2024

You are invited: Hospice education webinar

Policy UpdatesMedicare AdvantageJune 4, 2024

Clinical Criteria updates

Policy UpdatesMedicare AdvantageJune 3, 2024

Clinical Criteria updates — November 2023

Policy UpdatesMedicare AdvantageMay 29, 2024

Carelon Medical Benefits Management, Inc. updates

Medical Policy & Clinical GuidelinesCommercialMedicare AdvantageJune 27, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Updates to Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines

Medical Policy & Clinical GuidelinesCommercialJune 11, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Medical Policies and Clinical Guidelines updates for July 2024

Medical Policy & Clinical GuidelinesMedicare AdvantageMay 30, 2024

Medical Policies and Clinical Utilization Management Guidelines update

Medical Policy & Clinical GuidelinesMedicaid Managed CareJune 5, 2024

Medical Policies and Clinical Utilization Management Guidelines Update

Prior AuthorizationCommercialJune 19, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Carelon Medical Benefits Management, Inc. genetic testing code updates

Prior AuthorizationMedicaid Managed CareJune 20, 2024

Prior authorization requirement changes effective August 1, 2024

Prior AuthorizationMedicaid Managed CareJune 11, 2024

Prior authorization requirement changes

Reimbursement PoliciesCommercialJuly 1, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Reimbursement policy update: Incident to Services — Professional

Reimbursement PoliciesCommercialJuly 1, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Reimbursement policy update: Frequency Editing — Professional

Reimbursement PoliciesCommercialJuly 1, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

New reimbursement policy: Diagnostic Radiopharmaceuticals and Contrast Materials — Professional and Facility

Federal Employee Program (FEP)CommercialJuly 1, 2024

Antidepressant Medication Management (AMM)

PharmacyMedicare AdvantageJune 20, 2024

Anthem expands specialty pharmacy precertification list

PharmacyCommercialJuly 1, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Correction: Specialty pharmacy updates — July 2024

Quality ManagementMedicare AdvantageJuly 1, 2024

Understanding your role in the Health Outcomes Survey

OHBCBS-CDCRCM-061287-24

AdministrativeCommercialJuly 1, 2024

Timely receipt of other carrier EOB or rejection helps avoid timely filing denials

When working with another carrier, submit documentation from the other carrier when you send the claim to Anthem to help avoid the claim from denying for timely filing. You can submit the documentation and the claim through Availity Essentials using the Claims and Payments application.

If we are the secondary payer, we will need to receive an Explanation of Benefits (EOB) along with the claim submission to determine our payment amount. To avoid a timely filing denial, the documentation must demonstrate that submission to the other insurer was within Anthem’s timely filing limit and must reflect that it was received within the timely filing limit starting from the date of the remittance advice or Explanation of Payments.

If you submit to the other carrier first and receive a rejection, submit the denial letter from the other insurance carrier along with the claim. To avoid a timely filing denial, the denial letter must be dated and printed on letterhead, and the claim and documentation must be submitted to Anthem within the timely filing limit starting from the date of the denial letter.

When a claim is submitted to us as the primary payer, and we are the secondary payer, our claims system will deny the claim because we don’t have the EOB. This can delay your receiving payment and can also cause you to miss the timely filing guideline.

Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners.

Resource

Coordination of benefits — how to avoid timely filing denial

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-061117-24

ATTACHMENTS (available on web): Coordination of benefits — how to avoid timely filing denials (pdf - 0.32mb)

AdministrativeCommercialJuly 1, 2024

Anesthesia modifiers — professional editing update

Effective for all claims received on and after August 1, 2024, Anthem is updating its professional claims editing system to deny anesthesia services billed without the required anesthesia modifiers. According to industry-standard coding resources including the American Society of Anesthesiologists and AMA CPT® coding manuals, and the Anthem current commercial professional anesthesia services reimbursement policy, anesthesia modifiers are necessary to identify whether a procedure was personally performed, medically directed, or medically supervised.

The required modifiers to be reported by provider type are as follows:

Provider type
Required modifier(s)

Anesthesiologist

AA, AD, QK, or QY

CRNA or anesthesiologist assistant — medically directed

QX

CRNA — not medically directed

QZ

If you believe you have received a claim denial in error, follow the Anthem claim dispute process.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-061114-24

AdministrativeCommercialJuly 1, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Drugs and biologic

Effective October 1, 2024, Anthem is enhancing its claims editing system to ensure that claims billed with pharmaceutical drug procedure codes are reported with the appropriate Federal Drug Administration (FDA) approved indicators for on- and off-label use.

These enhanced claim edits provide an opportunity for Anthem to evaluate submitted claims for drug quality, safety, and effectiveness. The enhancement is to have the claims deny if not billed with the FDA indicator for on-/off-label use.

If you believe a claim reimbursement decision should be reviewed, please follow the normal claims dispute process outlined in the provider manual and include medical records that clarify whether the indication was approved through the governing agencies. You will only need to submit the portion(s) of the medical record that is relevant to the drug provided.

If you have questions about this notification, contact your contract manager or provider relationship management account representative.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-061244-24

AdministrativeCommercialMedicare AdvantageMedicaid Managed CareJune 18, 2024

Phoenix Sepsis Criteria for coding and billing pediatric sepsis

To ensure compliance with the coding and billing of a claim submitted with the diagnosis of sepsis for our pediatric members, we review clinical information (including treatment and medical management) and laboratory and diagnostic procedure findings in the medical records submitted for review. To conduct the review accurately and consistently, our review process for pediatric sepsis applies coding and documentation guidelines.

Beginning with admission dates of July 1, 2024, and later for members aged 29 days through 17 years of age, we will also apply the updated and most recent publication of the Society of Critical Care Medicine Pediatric Sepsis Definition Task Force criteria known as the Phoenix Sepsis Criteria, published in the Journal of the American Medical Association (JAMA) in January 2024.

Clinicians and facilities should apply the Phoenix Sepsis Criteria when determining at discharge if the pediatric patient’s clinical course supports the coding and billing of a diagnosis of sepsis. The claim may be subject to an adjustment in reimbursement when sepsis is found to be unsupported based on the Phoenix Sepsis Criteria.

Together, we can work towards improved outcomes.

jamanetwork.com/journals/jama/article-abstract/2814297

Anthem Blue Cross and Blue Shield and Anthem Blue Cross and Blue Shield Medicaid are trade names of Community Insurance Company. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CDCRCM-056042-24-CPN55116

AdministrativeCommercialJuly 1, 2024

CAA: Maintain your online provider directory information

Maintaining your online provider directory information is essential for member and healthcare partners to connect with you when needed. Access your online provider directory information by visiting anthem.com/provider. Then at the top of the webpage, choose Find Care. Review your information and let us know if any of your information has changed.

Updating your information

Anthem uses the provider data management (PDM) capability available on Availity Essentials to update your care provider or facility data. Using the Availity PDM capability meets the quarterly attestation requirement to validate care provider demographic data set by the Consolidated Appropriations Act (CAA).

PDM features include:

  • Updating care provider demographic information for all assigned payers in one location.
  • Attesting to and managing current care provider demographic information.
  • Monitoring submitted demographic updates in real-time with a digital dashboard.
  • Reviewing the history of previously verified data.

Accessing the PDM application

Log on to Availity.com and select My Providers > Provider Data Management to begin using PDM. Administrators will automatically be granted access to PDM. Additional staff may be given access to PDM by an administrator. To find your administrator, go to My Account Dashboard > My Account > Organization(s) > Administrator Information.

PDM training

PDM training is available:

  • Log on to Availity.com to learn about and attend one of our training opportunities.
  • On Availity.com, you can view the Availity PDM quick start guide.
  • Roster Automation Standard Template and Roster Automation Rules of Engagement training:
    • Listen to our recorded webinar on Availity.com.

Not registered for Availity yet?

If you aren’t registered to use Availity Essentials, signing up is easy and 100% secure. There is no cost for your care providers to register or to use any of our digital applications. Start by going to Availity.com and selecting New to Availity? Get Started at the top of the home screen to access the registration page. If you have more than one tax ID number (TIN), please ensure you have registered all TINs associated with your account. If you have questions regarding registration, reach out to Availity Client Services at 800-AVAILITY.

We are focused on reducing administrative burdens, so you can do what you do best — care for our members.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-060917-24-SRS60902

AdministrativeMedicaid Managed CareJanuary 1, 2024

New resources available for ePRAF

There are new resources available for providers to complete the Pregnancy Risk Assessment Form electronically, or ePRAF (Electronic Pregnancy Risk Assessment Form). To access this form, log in to the NurtureOhio website where you will find information on how to use the ePRAF.

Quality Enhancer Incentive Program for ePRAF

The Quality Enhancer Incentive Program provides increased payments to eligible providers who submit the ePRAF via the NurtureOhio website on behalf of their pregnant patients.

Technical Assistance Intervention Package for ePRAF

The Technical Assistance Intervention Package is a collection of resources, tools, and reporting that is designed to assist Providers in delivering high-quality pregnancy related care to their patients.

For more information on using the ePRAF, please contact us at ohiomedicaidprovider@anthem.com.

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CD-048680-23, OHBCBS-CD-049383-24-SRS48922, OHBCBS-CD-049390-24-SRS48922, OHBCBS-CD-049393-24-SRS48922, OHBCBS-CD-049391-24-SRS48922, OHBCBS-CD-049392-24-SRS48922, OHBCBS-CD-048922-24-SRS48922, OHBCBS-CD-049387-24-SRS48922, OHBCBS-CD-049384-24-SRS48922, OHBCBS-CD-049388-24-SRS48922, OHBCBS-CD-049389-24-SRS48922, OHBCBS-CD-049385-24-SRS48922

AdministrativeMedicaid Managed CareJuly 1, 2024

Anatomical modifiers

Beginning with claims processing on or after August 1, 2024, Anthem will use coding policies to support the use of anatomical modifiers. These policies were developed to promote national correct coding methods and to control improper coding that leads to incorrect payment. This update is part of continuing efforts to process claims accurately without having to request additional documentation from providers.

What are the policies for using anatomical modifiers in procedure coding?

CPT® and HCPCS Level II guidelines supporting the use of anatomic-specific modifiers were used to develop these policies, which validate the area or part of the body on which a procedure is performed. Procedure codes that do not specify right or left require the appropriate anatomical modifier. If an anatomical modifier is necessary to differentiate right or left and is not appended, the claim will be denied. Likewise, if a modifier is appended to a procedure code that does not match the appropriate anatomical site, the claim will be denied.

Action needed

CPT and HCPCS Level II guidelines support the following set of anatomical modifiers to facilitate correct coding for claims processing. Care providers are encouraged to follow these guidelines and append the modifiers relevant to the procedure code on the service line.

The anatomical modifiers which must be reported are:

Modifier

Description

E1–E4

Eyelids

FA, F1–F9

Fingers

TA, T1–T9

Toes

LC

Left circumflex, coronary artery

LD

Left anterior descending, coronary artery

RC

Right coronary artery

LT

Left side

RT

Right side

50

Bilateral

We are committed to a future of shared success. If you have questions about this communication or need assistance with any other item, contact your provider relationship management representative.

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CD-059557-24-CPN58952

Digital SolutionsCommercialJune 20, 2024

Digital-only authorization case status notification coming to you

In our previous communications, we shared information about using the Authorizations and Referrals application on Availity Essentials to receive digital notifications for your authorization cases and related decision letters, and we introduced the Preference Center for Authorization and Referrals where you can select your preferred method of communication. We are excited to announce that we launched the Preference Center for Authorization and Referrals in April and will start using your preferences there in July.

Here is a quick recap on how to receive digital notifications and set your preferred communication method for the status of your authorization cases.

Use the Authorizations and Referrals application for digital notifications:

  • Retrieve cases submitted digitally and non-digitally by your organization through Auth/Referral Inquiry; use the Pin to Dashboard feature to keep these cases on the Auth/Referral Dashboard, saving you from repeating the search in the future.
  • Find the most recent statuses of cases submitted by your organization on the Auth/Referral Dashboard — Select View Details in the Actions menu for case details, including decision letters. For pinned cases, select the case card to get the latest status and case details.

Access the Preference Center and set your preferences:

  • After logging in to Availity Essentials, select Payer Spaces from the top menu bar, then select the Anthem payer tile. Once in Payer Spaces, select the Preference Center application tile.
  • Select your organization and then set your communication preference (your default is Digital Access (Default) or if you prefer to receive paper surface mail, you can select Digital + Mail) for Authorization and Referrals:  
    • Adjust the preference for the tax IDs and NPIs of your organization to fit your business needs.
    • You can add more NPIs to your current registration and set the preferred communication mode for the new NPIs under the selected tax IDs.

Manage preferences (Availity administrators)

Availity Administrators can learn more about managing preferences related to Authorization Decision letters. After logging in to Availity Essentials, select Payer Spaces from the top menu bar, then select the Anthem payer tile. Once in Payer Spaces, select the Custom Learning Center application, then select the Resources section to view or download the Reference Guide on managing receipt of Authorization Decision letters.

With your help, we can continually build towards a future of shared success.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-060250-24-CPN60234

Digital SolutionsCommercialJuly 1, 2024

Coming soon — Use the Provider Enrollment application in Availity Essentials Payer Spaces to view your fee schedule

Care providers will soon be able to request specific fee schedules via the Provider Enrollment application in Availity Essentials. Enter your organizational information in the My Fee Schedule option, where you will be able to request and download your contracted rate(s).

More fee schedule options

Other exciting features include:

  • The ability for care providers to download the complete fee schedule for both standard and negotiated rates within minutes.
  • The function to pull historic fee schedules for up to three years, as well as current and future rate(s).
  • Rates updated daily and available the following day.
  • One centralized location to receive fee schedules.

How to access

To locate Provider Enrollment, access Availity Essentials, select your State, then select Payer Spaces, and finally select the Payer Tile.

Coming soon

Be on the lookout for future communications for when this feature will be live.

Through genuine collaboration, we can simplify access to care and help you deliver high-quality, equitable healthcare.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CM-061360-24

Digital SolutionsMedicare AdvantageMedicaid Managed CareJuly 1, 2024

Admission, discharge, and transfer information is now available for Medicare Advantage and Medicaid members

If you and your organization are focused on promoting evidence-based medicine and clinical quality performance, our Alerts Hub clinical notification tool, accessed through Availity Essentials, can help drive your success.

Our clinical notification application, Alerts Hub, offers admission, discharge, and transfer (ADT) notifications for Medicare Advantage and Medicaid members. For those members, Alerts Hub offers a simple way to view a list of patients who have been admitted to the hospital or visited the emergency room.

Discover what users across the country already know.

Alerts Hub offers timely, actionable information to help your organization reach out to patients who can benefit from transitions in care planning or other interventions following inpatient or emergency care.

Viewing and responding to ADT notifications with outreach to patients can help drive your organizations’ clinical quality and cost of care performance in value-based care arrangements —More importantly, it helps drive better outcomes for your patients.

Get started today.

We are committed to finding solutions that help our care provider partners offer quality services to our members. To access Alerts Hub, log on to Availity Essentials, select Payer Spaces, then select Alerts Hub. New users will need to register and set preferences. Registered users will receive daily notification emails with a summary of relevant alerts and a reminder to view details in Alerts Hub. Be sure to check your junk or spam folders if you aren’t receiving messages in your inbox.

Need more help? The Availity Custom Learning Center offers a range of training materials that can help you get up to speed quickly so that you can take advantage of all Alerts Hub has to offer.

Contact us.

Chat with Payer is available during normal business hours. Get answers to your questions about eligibility, benefits, authorizations, claims status, and more. To access Availity Essentials, go to Availity.com and select the appropriate payer space tile from the drop-down. Then, select Chat with Payer and complete the pre-chat form to start your chat.

For additional support, visit the Contact Us section of our provider website.

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CDCR-060642-24-CPN59897

Education & TrainingCommercialJune 13, 2024

Faster notification of EDI corrected claims errors

For those providers and their corresponding vendors (either billing services or clearinghouses) who submit corrected claims through EDI, we’re enhancing the 277CA to notify you of submission errors discovered during our claims processing. Although you’ll continue to receive physical mail notifications related to claims processing issues, the 277CA notifications can expedite the turnaround time by highlighting submission issues upfront.

Now, the 277CA will also communicate the following messages:

  • Tax ID and NPI are not registered.
  • Billed place of treatment doesn’t correspond with the place of service.
  • Rendering provider isn’t valid for the service date.
  • Billing NPI doesn’t align with the claim’s tax ID.

Despite the addition of this new feature, there will be no reductions in the services we already provide. Our hope is that this change will augment the speed and communication of our service.

Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-060850-24-CPN59863

Education & TrainingCommercialMedicare AdvantageMedicaid Managed CareJuly 1, 2024

July is Disability Awareness Month

We hope you are finding our monthly observance articles helpful and informative. We will continue to feature these monthly articles to keep you informed about our resources that are here to support you in caring for all of our members.

We strive to advance health equity so everyone has a fair opportunity to be at their healthiest. As we reduce barriers to whole health — physical, behavioral, and social — and personalize the healthcare journey, we can more effectively advance health equity. While focusing on understanding member needs, we actively develop educational tools for providers.

In recognition of July as Disability Awareness Month, and to commemorate the signing of the Americans with Disabilities Act (ADA) in 1990 that promotes equal rights and accessibility for people with disabilities, we are introducing three eLearning resources and tools on My Diverse Patients. This site offers a comprehensive repository of resources for providers to help support the needs of diverse patients and address disparities. Availability of multiple free continuing medical education (CME) courses with CMEs are offered through the American Academy of Family Physicians (AAFP).

For the month of July, our featured eLearning Resources & Tools are:

  • Health Equity Framework for People with Disabilities:
    • This policy brief provides the rationale for the need for an all-of-government approach to achieve health equity in the United States and its territories for the largest unrecognized minority group in this country — the over 61 million people with disabilities — and sets forth a framework to achieve health equity for all people with disabilities. Disability is a natural part of the human condition, which occurs across all ages, genders, races, ethnicities, languages, and social groups.
  • Health Equity for People with Disabilities:
    • The CDC’s Division of Human Development and Disability (DHDD) works to promote health and reduce health inequities for people with disabilities of all ages so they can participate fully in all aspects of their communities throughout their lives and have the opportunity to achieve all they set out to do.
  • Connections Between Health Equity and Disability:
    • When it comes to healthcare, significant disparities abound between people with disabilities and able-bodied people. From physical barriers and discrimination to financial hurdles and a lack of available resources, access to healthcare is alarmingly inequitable for people with disabilities around the world.

We're pleased to offer these resources as we work together to deliver high-quality, equitable healthcare.

Anthem Blue Cross and Blue Shield and Anthem Blue Cross and Blue Shield Medicaid are trade names of Community Insurance Company. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-ALL-CDCRCM-060726-24-CPN60345

Education & TrainingMedicaid Managed CareJuly 1, 2024

Access instant health plan information via Availity Essentials

Availity Essentials, the secure multi-payer website, allows access to Anthem digital applications and training resources. Availity Essentials provides access to real-time information and instant responses in a consistent format, regardless of the payer.

If you have been using Availity Essentials for other Anthem plans, you will be able to seamlessly transition to using the website for Medicaid members during patient check-ins and checkouts.

If you are new to Availity Essentials, register now for secure website access so your organization will be ready to benefit from easy, instant access to health plan information.

Some of the Availity Essentials multi-payer self-service features available for Anthem include:

  • Eligibility and benefits.
  • Claims status.
  • Claims disputes.
  • Medical attachments.
  • Authorization status and clinical appeals.

To find additional digital applications exclusive to Anthem, visit Payer Spaces on Availity Essentials. Some of the most frequently used applications are:

  • Chat with payer: Start a live chat to get questions answered through a real-time, online discussion.
  • Custom Learning Center: Locate job aids and courses illustrating navigation of applications and electronic data interchange (EDI) transactions.
  • Patient360: Access member-centric clinical and case management data.
  • Precertification Look Up Tool: Verify if outpatient services require prior authorization.
  • Provider online reporting: Retrieve Member Panel reports of members assigned to individual providers or groups.
  • Remittance inquiry: View, print, and save a copy of your remittance advice.

Not registered with Availity Essentials? Take these steps to get started

First, your organization needs to assign an Availity Essentials administrator to initiate registration. To begin the process, the administrator should visit Availity.com, select Register, and complete the online form. For more details on registration, visit Learn About Availity Essential Registration. The Registration webpage includes a link with information on live webinars you can join each month. An instructor will go through the steps necessary to register and get started on Availity Essentials.

As an administrator or a user on Availity Essentials, check out the Provider Learning Hub and begin taking on demand courses.

The Provider Learning Hub offers on-demand onboarding modules for new administrators and users. To access this Availity training, you need to be registered and have a user ID. These modules are also located on the Availity Learning Center. From the Availity Essentials top navigation bar, select Help & Training | Get Trained. For any course, search by keyword such as administrator onboarding or filter by category to locate the course.

Availity Essentials live training webinars for all providers servicing Anthem members

The sessions will cover the digital applications that are available to use for the health plan. The instructor will demonstrate navigation and features of eligibility and benefits, claims disputes, medical attachments, and more. To enroll for a webinar session, select this link: Provider Availity Essentials Training. You can also log on to Availity, select Help & Training > Get Trained. The ALC catalog opens in a new browser tab. Enter OHBC in the search field to enroll for these live webinars. Registration for the webinars is available now.

Do you have questions regarding Availity Essentials registration?

Call Availity Client Services at 800-AVAILITY (800-282-4548). Availity Client Services is available Monday to Friday from 8 a.m. to 8 p.m. Eastern time (excluding holidays) to answer your registration questions.

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CD-061224-24

Education & TrainingCommercialMarch 12, 2024

Important reminder: The correct original claim number must be included if submitting a corrected claim

When we receive a corrected claim and it doesn’t have the original claim number, or the original claim number is not correctly entered, we are not able to process it because we’re not able to connect it to the original claim.

  1. For providers and their vendors (clearinghouses or billing services) submitting a corrected claim through EDI, we will send you a 277CA EDI Response Report acknowledging that we’ve received the submission, but are not able to process it:
    1. In this instance, you can either submit a new corrected claim with the original claim ID number or submit the corrected claim as an original claim if you do not have the original claim ID number.
    2. It is important that you submit proof of timely filing when resubmitting the correction or the original claim so we can ensure the claim is processed according to the timely filing guidelines.
  1. For providers using Claims Status application on Availity.com, you will not be able to access the corrected claim if it was rejected on the 277CA EDI Response Report:
    1. In this instance, you can either submit a new corrected claim with the original claim ID number or submit the corrected claim as an original claim if you do not have the original claim ID number.
    2. It is important that you submit proof of timely filing when resubmitting the correction or the original claim so we can ensure the claim is processed according to the timely filing guidelines.

We’ve also developed a training video that can help you reduce duplicate claims along with a training guide called Making the Claims Process Work for You to help you properly submit a corrected claim. Access the video and download the guide here. Provider information is required to view this training; however, you will only be prompted to enter this information the first time viewing this training.

If you have questions about submitting a corrected claim, reach out to your provider representative or work with your EDI vendor to ensure you are receiving the 277CA Response Report.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-049145-23-CPN48099, MULTI-BCBS-CM-061597-24-CPN61590

Education & TrainingMedicaid Managed CareJuly 1, 2024

Join our Provider Advisory Council

Anthem invites our Medicaid care providers in Ohio to participate in our Provider Advisory Council. The meeting’s intent is to collaborate with our provider community and gather input, discuss trends, identify challenges, and remove barriers — ultimately improving the healthcare delivery system.

If you are interested in participating, sign up by visiting the link below.

https://s-us.chkmkt.com/?e=313263&h=3706BA345B2C543&l=en

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CD-059831-24

Education & TrainingMedicaid Managed CareJuly 1, 2024

You are invited: Behavioral health provider orientation

Anthem is pleased to announce the next behavioral health provider orientation.

Wednesday, July 24, 2024 | 11 a.m. ET
Behavioral health orientation


Please join us to learn more about working with us and supporting your patients, our members.

To register, follow the link:

https://s-us.chkmkt.com/?e=388705&d=l&h=F70FB4945B9D3AF&l=en

If you have questions, contact your provider relationship account manager or send an email to OhioMedicaidProvider@anthem.com.

We’re committed to active involvement with our care provider partners and going beyond the contract to create a real impact on the health of our communities.

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CD-058796-24

Education & TrainingMedicaid Managed CareJuly 1, 2024

You are invited: Provider orientation

The Provider Relationship Account Management team for Anthem will host our next Provider Orientation on July 16, 2024, at 11:00 a.m. ET. Our orientation will cover everything you need to know about working with us.

Tuesday, July 16, 2024 | 11:00 a.m. ET
Registration link: https://tinyurl.com/22mt9bkf

If you have questions, please contact your Provider Relationship Account Manager or email OhioMedicaidProvider@anthem.com.

We are committed to working together to achieve improved outcomes and foster genuine collaboration with our care provider partners.


Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CD-058794-24

Education & TrainingMedicaid Managed CareJuly 1, 2024

You are invited: Hospice education webinar

All hospice providers are welcome to attend.

The Ohio Medicaid Provider Relationship Account Management team invites all hospice providers to attend a hospice education webinar. Our webinar will provide education on Anthem’s billing guidelines.

July 24, 2024 | 2 p.m. ET
Hospice education webinar

Register

Register at this link: https://us.mar.medallia.com/?e=394452&d=l&h=7768CD09F2DFB5F&l=en

If you have questions, write to ohmedicaidencpesupport@elevancehealth.com.

We are committed to working together to achieve improved outcomes and foster genuine collaboration with our care provider partners.

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CD-060088-24

Policy UpdatesMedicare AdvantageJune 4, 2024

Clinical Criteria updates

Effective July 6, 2024

Summary

On November 17, 2023, and March 21, 2024, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.

Please see the explanation/definition for each category of Clinical Criteria below:

  • New: newly published criteria
  • Revised: addition or removal of medical necessity requirements, new document number
  • Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other providers in your practice and office staff.

Please note:

  • The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
  • This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective date

Clinical Criteria number

Clinical Criteria title

New or revised

July 6, 2024

*CC-0261

Winrevair (sotatercept-csrk)

New

July 6, 2024

*CC-0125

Opdivo (nivolumab)

Revised

July 6, 2024

*CC-0003

Immunoglobulins

Revised

July 6, 2024

CC-0033

Xolair (omalizumab)

Revised

July 6, 2024

*CC-0062

Tumor Necrosis Factor Antagonists

Revised

July 6, 2024

CC-0121

Gazyva (obinutuzumab)

Revised

July 6, 2024

CC-0201

Rybrevant (amivantamab-ymjw)

Revised

July 6, 2024

*CC-0251

Ycanth (cantharidin)

Revised

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CR-059942-24-CPN59599

Policy UpdatesMedicare AdvantageJune 3, 2024

Clinical Criteria updates — November 2023

Summary: On February 24, 2023, September 11, 2023, and November 17, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.

Please see the explanation/definition for each category of Clinical Criteria below:

  • New: newly published criteria
  • Revised: addition or removal of medical necessity requirements, new document number
  • Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other providers in your practice and office staff.

Please note:

  • The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
  • This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective Date

Clinical Criteria Number

Clinical Criteria Title

New or Revised

July 7, 2024

*CC-0252

Adzynma (ADAMTS13, recombinant-krhn)

New

July 7, 2024

*CC-0253

Aphexda (motixafortide)

New

July 7, 2024

*CC-0254

Zilbysq (zilucoplan)

New

July 7, 2024

CC-0130

Imfinzi (durvalumab)

Revised

July 7, 2024

CC-0223

Imjudo (tremelimumab-actl)

Revised

July 7, 2024

*CC-0059

Selected Injectable NK-1 Antiemetic Agents

Revised

July 7, 2024

CC-0074

Akynzeo (fosnetupitant and palonosetron) for injection

Revised

July 7, 2024

*CC-0065

Agents for Hemophilia A and von Willebrand Disease

Revised

July 7, 2024

CC-0124

Keytruda (pembrolizumab)

Revised

July 7, 2024

CC-0150

Kymriah (tisagenlecleucel)

Revised

July 7, 2024

CC-0187

Breyanzi (lisocabtagene maraleucel)

Revised

July 7, 2024

CC-0133

Aliqopa (copanlisib)

Revised

July 7, 2024

CC-0205

Fyarro (sirolimus albumin bound)

Revised

July 7, 2024

CC-0127

Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj)

Revised

July 7, 2024

*CC-0226

Elahere (mirvetuximab)

Revised

July 7, 2024

CC-0125

Opdivo (nivolumab)

Revised

July 7, 2024

CC-0058

Sandostatin and Sandostatin LAR (Octreotide) / Octreotide Agents

Revised

July 7, 2024

*CC-0009

Lemtrada (alemtuzumab) for the Treatment of Multiple Sclerosis

Revised

July 7, 2024

*CC-0014

Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis

Revised

July 7, 2024

*CC-0011

Ocrevus (ocrelizumab)

Revised

July 7, 2024

*CC-0174

Kesimpta (ofatumumab)

Revised

July 7, 2024

*CC-0020

Natalizumab Agents (Tysabri, Tyruko)

Revised

July 7, 2024

*CC-0032

Botulinum Toxin

Revised

July 7, 2024

*CC-0068

Growth Hormone

Revised

July 7, 2024

*CC-0173

Enspryng (satralizumab-mwge)

Revised

July 7, 2024

*CC-0170

Uplizna (inebilizumab-cdon)

Revised

July 7, 2024

*CC-0199

Empaveli (pegcetacoplan)

Revised

July 7, 2024

*CC-0041

Complement Inhibitors

Revised

July 7, 2024

*CC-0071

Entyvio (vedolizumab)

Revised

July 7, 2024

*CC-0064

Interleukin-1 Inhibitors

Revised

July 7, 2024

*CC-0042

Monoclonal Antibodies to Interleukin-17

Revised

July 7, 2024

*CC-0066

Monoclonal Antibodies to Interleukin-6

Revised

July 7, 2024

*CC-0050

Monoclonal Antibodies to Interleukin-23

Revised

July 7, 2024

*CC-0078

Orencia (abatacept)

Revised

July 7, 2024

*CC-0063

Ustekinumab Agents

Revised

July 7, 2024

*CC-0062

Tumor Necrosis Factor Antagonists

Revised

July 7, 2024

CC-0003

Immunoglobulins

Revised

July 7, 2024

*CC-0002

Colony Stimulating Factor Agents

Revised

July 7, 2024

CC-0247

Beyfortus (nirsevimab)

Revised

July 7, 2024

CC-0072

Vascular Endothelial Growth Factor (VEGF) Inhibitors

Revised

July 7, 2024

CC-0010

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors

Revised

July 7, 2024

CC-0209

Leqvio (inclisiran)

Revised

July 7, 2024

*CC-0182

Iron Agents

Revised

July 7, 2024

*CC-0086

Spravato (esketamine) Nasal Spray

Revised

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CR-050483-24-CPN49884

Policy UpdatesMedicare AdvantageMay 29, 2024

Carelon Medical Benefits Management, Inc. updates

This article was updated as of August 23, 2024.

Effective September 1, 2024, Anthem will transition to the following Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines for medical necessity/clinical appropriateness reviews for requested interventions. This article is to communicate the plan adoption of these Carelon Medical Benefits Management, Inc. guidelines. This does not equate to the presence of a prior authorization requirement. In the event a prior authorization requirement for these services will be implemented, a separate notice will be distributed before the addition of any prior authorization requirements.

  • Site of Care Guidelines:
    • Site of Care for Advanced Imaging
    • Rehabilitative Site of Care
    • Surgical Site of Care

Please share this notice with other members of your practice and office staff.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CR-055356-24-CPN54514, MULTI-ALL-CDCR-066460-24

Medical Policy & Clinical GuidelinesCommercialMedicare AdvantageJune 27, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Updates to Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines

Effective for dates of service on and after October 20, 2024, the following updates will apply to the Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines. As part of the Carelon Medical Benefits Management guideline annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe, and affordable healthcare services.

Radiology:

  • Brain Imaging:
    • Added indications for MRI and amyloid beta PET imaging in Alzheimer disease to address patients considering or receiving lecanemab
  • Spine Imaging:
    • Changed Perioperative and Periprocedural Imaging to Postoperative and Postprocedural Imaging; pre-procedure requests should be reviewed based on more specific indication
  • Extremity Imaging:
    • Separated criteria for osteomyelitis and septic arthritis into separate indications; US or arthrocentesis as preliminary tests were placed only in the septic arthritis indication
  • Vascular Imaging:
    • CTA/MRA Head addition for chronic posterior circulation Stroke/TIA presentations (CTA/MRA neck already allowed, intracranial eval needed for full extent of anatomy)
    • Lower Extremity PAD: Updated physiologic testing parameters and added allowance for ischemic signs/symptoms at presentation, in alignment with ACR Appropriateness Criteria
    • Suboptimal imaging option downgrades/removals in Brain, Head and Neck, and Abdomen/Pelvis

Cardiovascular:

  • Imaging of the Heart:
    • Resting Transthoracic Echocardiography (TTE)
    • Expanded frequency of echocardiographic evaluation in patients on mavacamten for treatment of hypertrophic obstructive cardiomyopathy (HOCM)
    • Expanded criteria for echocardiographic evaluation to allow a single screening for cardiac disease in patients undergoing evaluation for solid organ or hematopoietic cell transplant
  • Cardiac Resynchronization Therapy:
    • Exclusion added for Wireless CRT
  • Diagnostic Coronary Angiography:
    • Criteria reaffirmed — no changes
  • Endovascular Revascularization:
    • Added indication for endovascular venous arterialization of the tibial or peroneal veins
    • Exclusions added for endovenous femoral-popliteal arterial revascularization with transcatheter placement of intravascular stent and intravascular lithotripsy
    • Also exclusion added for atherectomy (clarification)
  • Implantable Cardioverter Defibrillators:
    • Transvenous ICD placement
    • Expanded criteria for transvenous ICD to include phospholamban, filamin-C, and lamin A/C cardiomyopathies
  • Percutaneous Coronary Intervention:
    • Exclusion added for percutaneous transluminal coronary lithotripsy
  • Permanent Implantable Pacemakers:
    • Device replacement
    • Added criteria for permanent implantable pacemaker device replacement
    • Single chamber leadless pacemakers
    • Clarified that criteria for single chamber leadless pacemaker apply to the right ventricle
    • Exclusion added for right atrial single chamber leadless pacemakers
    • Dual chamber leadless pacemakers
    • Exclusion added for dual chamber leadless pacemakers

Genetic Testing:

  • Chromosomal Microarray Analysis:
    • Clarified recommendations for Genetic Counseling
    • Clarified requirements for postnatal evaluation of individuals with:
    • Congenital or early onset epilepsy (before age 3 years) without suspected environmental causes
    • Autism spectrum disorder, developmental delay, or intellectual disability with no identifiable cause (idiopathic)
    • Clarified prenatal evaluation of a fetus with a structural fetal anomaly noted on ultrasound
  • Pharmacogenomic Testing:
    • Added APOE testing
  • Polygenic Risk Scores renamed Predictive and Prognostic Polygenic Testing:
    • Broadened guideline scope to include polygenic expression prognostic testing and multivariable prognostic genetic testing (essentially clarifications), and moved these tests to exclusions as they are considered not medically necessary
    • Retitled guideline to Predictive and Prognostic Polygenic Testing to address this change in scope.
  • Somatic Testing of Solid Tumors:
    • Breast Cancer
    • Clarified gene expression profiling is to guide adjuvant therapy for localized Breast Cancer
  • Whole Exome and Whole Genome Sequencing:
    • Expanded WES criteria to include congenital or early onset epilepsy (before age 3) without suspected environmental etiology and added other clarifications.
    • Clarified well-delineated genetic syndrome in criterion for multiple anomalies
    • Clarified Genetic Counseling details for WES

MSK:

  • Sacroiliac Joint Fusion:
    • New medical necessity criteria for open SI joint fusion
    • As an adjunct to sacrectomy or partial sacrectomy related to tumors involving the sacrum
    • As an adjunct to the medical treatment of sacroiliac joint infection/sepsis (for example, osteomyelitis, pyogenic sacroiliitis)
    • For severe traumatic injuries associated with pelvic ring disruption (for example, pelvic ring fractures, acetabular fracture, spinopelvic dissociation)
    • During multi-segment spinal constructs (for example, correction of deformity in scoliosis or kyphosis surgery) extending to the ilium as part of medically necessary lumbar spine fusion procedures
    • Open SI joint fusion is not medically necessary for poorly defined low back pain and sacral insufficiency fractures.
  • Spine Surgery:
    • Lumbar Discectomy, Foraminotomy, and Laminotomy
    • Added exclusion for annular closure device
    • Lumbar Laminectomy
    • Expanded timeframe for imaging lumbar disc herniation (9 months) and lumbar spinal stenosis (12 months)

Radiation Oncology:

  • Removed criteria for hyperthermia
  • Clarified inclusion criteria of the RTOG 1112 protocol.

Sleep Disorder Management:

  • Expanded definitions and terminology
  • Expanded documentation of hypoventilation
  • Expanded criteria for home and in-lab sleep studies
  • Added contraindication to APAP titration for use of supplemental oxygen
  • Removed home sleep apnea testing (HSAT) as an option in medical necessity of MSLT/MWT for suspected narcolepsy
  • Management of OSA using Implanted Hypoglossal Nerve Stimulators — Narrowed age range (raised lower limit to 13) for HNS in individuals with Down syndrome and OSA to align with age range suggested by FDA
  • Miscellaneous Devices section added: electronic positional therapy and neuromuscular electrical training of the tongue musculature are considered not medically necessary due to lack of high-quality evidence

As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management using the following:

  • Access Carelon Medical Benefits Management’s provider portal directly at providerportal.com:
  • Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.

If you have questions related to guidelines, please contact Carelon Medical Benefits Management via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines here.

Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CRCM-059470-24-CPN58860

Medical Policy & Clinical GuidelinesCommercialJune 11, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Medical Policies and Clinical Guidelines updates for July 2024

The following Anthem Medical Polices and Clinical Guidelines were reviewed for Indiana, Kentucky, Missouri, Ohio, and Wisconsin.

To view Medical Policies and utilization management guidelines, go to Anthem.com > Select Providers > Select your state > Under Provider Resources, select Policies, Guidelines & Manuals.

To help determine if prior authorization is needed for Anthem members, go to Anthem.com > Select Providers > Select your state > Under Claims > Select Prior Authorization. You can also call the prior authorization phone number on the back of the member’s ID card.

To view Medical Policies and utilization management guidelines applicable to members enrolled in the Blue Cross and Blue Shield Service Benefit Plan (commonly referred to as the Federal Employee Program® (FEP®)), visit fepblue.org > Policies & Guidelines.

Below are the new Medical Policies and/or Clinical Guidelines that have been approved:

Policy/guideline

Information

Effective date

CG-SURG-118 Intraocular Anterior Segment Aqueous Drainage Devices (without extraocular reservoir)

  • Moved content from SURG.00103 to new Clinical UM Guideline with the same title
  • INV&NMN changed to NMN as a result of MP to CUMG transition

10/1/2024

CG-SURG-119 Treatment of Varicose Veins (Lower Extremities)

  • Moved content from SURG.00037 to new Clinical UM Guideline with the same title
  • INV&NMN changed to NMN as a result of MP to CUMG transition

10/1/2024

CG-SURG-120 Vagus Nerve Stimulation

  • Moved content from SURG.00007 to new Clinical UM Guideline with the same title
  • INV&NMN changed to NMN as a result of MP to CUMG transition

10/1/2024

OR-PR.00008 Osseointegrated Limb Prostheses

  • Outlines the MN and NMN criteria for the use of osseointegrated (bone-anchored) prosthetic devices for improving the mobility and function of people who have had limb loss

10/1/2024

SURG.00162 Implantable Shock Absorber for Treatment of Knee Osteoarthritis

  • Use of an implantable shock absorber device for treatment of osteoarthritis of the knee is considered INV&NMN

10/1/2024

* Denotes prior authorization required

Below are the current Clinical Guidelines and/or Medical Policies we reviewed and updates that were approved:

Policy/guideline

Information

Effective date

ANC.00008 Cosmetic and Reconstructive Services of the Head and Neck

Added existing codes 21086, L8045 related to auricular prostheses considered MN or REC when criteria are met

4/10/2024

CG-BEH-02 Adaptive Behavioral Treatment

Criteria for these services have been transitioned to MCG guidelines

6/1/2024

CG-DME-31 Powered Wheeled Mobility Devices

Added new HCPCS code E2298 effective 4/1/2024 replacing deleted code E2300 for power seating system, also added K0108 NOC code

4/1/2024

CG-MED-68 Therapeutic Apheresis

Added erythropoietic protoporphyria, liver disease to the plasmapheresis and RBC exchange and heart transplantation, desensitization /rejection prophylaxis to the plasmapheresis MN sections
Added ICD-10-CM codes E80.0, K77 considered MN when criteria are met for plasmapheresis and cytapheresis

4/10/2024

LAB.00025 Topographic Genotyping

Added existing NOC code 89240 which may be used for this service

4/10/2024

LAB.00039 Combined Pathogen Identification and Drug Resistance Testing

Previously Titled: Pooled Antibiotic Sensitivity Testing

• Revised title
• Revised Position Statement to address “combined pathogen identification and drug resistance” testing
Added existing CPT® PLA codes 0141U, 0142U, 0321U & 0370U, 0369U previously addressed in CG-LAB-17 (MN criteria), and 0373U previously addressed in CG-LAB-14 (was NMN), all considered INV&NMN; removed 81479 NOC

4/10/2024

LAB.00046 Testing for Biochemical Markers for Alzheimer’s Disease

Added CPT PLA code 0445U effective 4/1/2024 for Elecsys® PhosphoTau (181P) CSF (pTau181) and βAmyloid (1-42) CSF II (Abeta 42) Ratio, considered INV&NMN

4/1/2024

MED.00125 Biofeedback and Neurofeedback

Added new HCPCS code S9002 effective 4/1/2024 for home biofeedback device, considered INV&NMN

4/1/2024

RAD.00059 Catheter-based Embolization Procedures for Malignant Lesions Outside the Liver

Added new HCPCS code C9797 effective 4/1/2024 for embolization, considered INV&NMN for specific diagnoses

4/1/2024

SURG.00011 Gene Mutation Testing for Cancer Susceptibility and Management

• Revised MN statement to include Cortiva and Surgimend for breast reconstruction
• Revised MN statement to include EPICEL, Integra Omnigraft Dermal Regeneration Template, and ReCell for the treatment of partial and deep thickness burns
• Revised MN statement to include Biovance and Oasis for the treatment of diabetic foot ulcers
• Revised NMN statement to align with revisions to MN statements
• Added new products to the INV&NMN statement

4/1/2024

SURG.00105 Bicompartmental Knee Arthroplasty

Criteria for these services have been transitioned to Carelon Medical Benefits Management, Inc. Musculoskeletal guidelines

6/1/2024

SURG.00126 Irreversible Electroporation

Added new ICD-10-PCS code 02583ZF for irreversible electroporation of cardiac conduction mechanism, considered INV&NMN

4/1/2024

SURG.00145 Mechanical Circulatory Assist Devices (Ventricular Assist Devices, Percutaneous Ventricular Assist Devices and Artificial Hearts)

• Revised pVAD criteria to include ECMO as concomitant therapy
• Revised Total Artificial Heart criteria for simplification

4/10/2024

SURG.00154 Microsurgical Procedures for the Prevention or Treatment of Lymphedema

Added ICD-10-PCS codes 0DXU0ZV, 0DXU0ZW, 0DXU0ZX, 0DXU0ZY, 0DXU4ZV, 0DXU4ZW, 0DXU4ZX, 0DXU4ZY effective 4/1/2024 for omentum transfer, considered INV&NMN for lymphedema diagnoses

4/1/2024

SURG.00157 Minimally Invasive Treatment of the Posterior Nasal Nerve to Treat Rhinitis

Added note regarding CPT code 30117 when used for posterior nasal nerve ablaton

4/1/2024

SURG.00158 Implantable Peripheral Nerve Stimulation Devices as a Treatment for Pain

Added new HCPCS code A4438 effective 4/1/2024 for a component of the NALU device, considered INV&NMN when specified for peripheral nerve

4/1/2024

TRANS.00028 Hematopoietic Stem Cell Transplantation for Hodgkin Disease and non-Hodgkin Lymphoma

• Updated formatting in Position Statement section
• In the MN Position Statement section for NHL, created criterion B3
• In the INV&NMN section for NHL, updated bullet “A” by adding “when criteria above are not met, including”
• Added ICD-10-CM diagnosis codes C91.50-C91.52 MN when criteria are met for lymphoma

4/10/2024

TRANS.00033 Heart Transplantation

Added CPT 33929 previously addressed in SURG.00145, considered MN when criteria are met

4/10/2024

TRANS.00038 Thymus Tissue Transplantation

Added endocrine procedure NOC code 60699

4/10/2024

* Denotes prior authorization required

Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-060651-24

Medical Policy & Clinical GuidelinesMedicare AdvantageMay 30, 2024

Medical Policies and Clinical Utilization Management Guidelines update

Effective July 1, 2024

The Medical Policies, Clinical Utilization Management (UM) Guidelines and Third-Party Criteria below were developed and/or revised during Q4 2023. Note, several policies and guidelines were revised to provide clarification only and are not included. Some may have expanded rationales, medical necessity indications or criteria and some may involve changes to policy position statements that might result in services that previously were covered being found to be not medically necessary.

Please share this notice with other providers in your practice and office staff.

To view a guideline, visit anthem.com/medicareprovider > Providers > Provider Resources > Policies, Guidelines & Manuals.

Notes/updates:

Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.

  • MED.00146 - Gene Therapy for Sickle Cell Disease
    • Outlines the Medically Necessary and Investigational & Not Medically Necessary criteria for Gene therapy for sickle cell disease
  • RAD.00068 - Myocardial Strain Imaging
    • Myocardial strain imaging in considered Investigational & Not Medically Necessary for all indications
  • SURG.00026 - Deep Brain, Cortical, and Cerebellar Stimulation
    • Reformatted Position Statement and added headers
    • Reformatted Medically Necessary statements to move target treatment areas into criteria
    • Revised Medically Necessary statement for primary dystonia to remove dystonia manifestation types
    • Reformatted Medically Necessary statements for DBS for Parkinson’s, primary dystonia, and OCD
    • Reformatted Medically Necessary statements for epilepsy
    • Revised DBS for epilepsy Medically Necessary statement regarding non-epileptic seizures
    • Revised Position Statement to add revision/replacement Medically Necessary and Investigational & Not Medically Necessary statements for DBS, cortical stimulation, and battery
    • Revised and reformatted Investigational & Not Medically Necessary statements
  • SURG.00097 - Scoliosis Surgery
    • Revision to Position Statement formatting
    • Added Medically Necessary and Investigational & Not Medically Necessary criteria for revision, replacement, or removal of vertebral body tethering to Position Statement
  • SURG.00142 - Genicular Procedures for Treatment of Knee Pain
    • Previously titled: Genicular Nerve Blocks and Ablation for Chronic Knee Pain
    • Revised title
    • Added genicular artery embolization to the scope of document
    • Revised Position Statement to add genicular artery embolization as Investigational & Not Medically Necessary
  • CG-DME-42 - Continuous Glucose Monitoring Devices
    • Previously titled: Continuous Glucose Monitoring Devices and External Insulin Infusion Pumps
    • Revised title
    • Moved content related to external insulin pumps to new document CG-DME-51 and automated insulin delivery systems to new document CG-DME-50
    • Revised existing Medically Necessary and Not Medically Necessary statements
  • CG-DME-52 - Continuous Passive Motion Devices in the Home Setting
    • Use of a continuous passive motion (CPM) device in the home setting is considered Not Medically Necessary for all indications
  • CG-MED-94 - Vestibular Function Testing
    • Outlines the Medically Necessary and Not Medically Necessary criteria for vestibular function testing
  • CG-SURG-09 - Temporomandibular Disorders
    • Revised formatting of Medically Necessary statement
    • Revised surgical procedures criteria
    • Added MIRO Therapy to Not Medically Necessary statement
  • CG-SURG-70 - Gastric Electrical Stimulation
    • Added Medically Necessary and Not Medically Necessary criteria to Clinical Indications for removal, revision, or replacement of a gastric electrical stimulator

Medical Policies

On November 9, 2023, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Anthem. These medical policies take effect July 1, 2024.

Publish date

Medical Policy number

Medical Policy title

New or revised

1/3/2024

LAB.00026

Systems Pathology and Multimodal Artificial Intelligence Testing for Prostate Cancer

Previously titled: Systems Pathology Testing for Prostate Cancer

Revised

1/3/2024

LAB.00046

Testing for Biochemical Markers for Alzheimer’s Disease

Revised

1/3/2024

LAB.00050

Metagenomic Sequencing for Infectious Disease in the Outpatient Setting

Conversion new

1/3/2024

MED.00057

MRI Guided High Intensity Focused Ultrasound Ablation for Non-Oncologic Indications

Revised

1/18/2024

*MED.00146

Gene Therapy for Sickle Cell Disease

New

1/3/2024

*RAD.00068

Myocardial Strain Imaging

New

1/3/2024

SURG.00010

Treatments for Urinary Incontinence

Revised

12/28/2023

*SURG.00026

Deep Brain, Cortical, and Cerebellar Stimulation

Revised

12/28/2023

*SURG.00097

Scoliosis Surgery

Revised

1/3/2024

*SURG.00142

Genicular Procedures for Treatment of Knee Pain

Previously titled: Genicular Nerve Blocks and Ablation for Chronic Knee Pain

Revised

1/3/2024

TRANS.00027

Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors

Revised

Clinical UM Guidelines

On November 9, 2023, the MPTAC approved the following Clinical UM Guidelines applicable to Anthem. These guidelines were adopted by the medical operations committee for Medicare Advantage members on January 4, 2024. These guidelines take effect July 1, 2024.

Publish date

Clinical UM Guideline number

Clinical UM Guideline title

New or revised

1/3/2024

*CG-DME-42

Continuous Glucose Monitoring Devices

Previously titled: Continuous Glucose Monitoring Devices and External Insulin Infusion Pumps

Revised

1/3/2024

CG-DME-44

Electric Tumor Treatment Field (TTF)

Revised

1/3/2024

CG-DME-50

Automated Insulin Delivery Systems

Conversion new

1/3/2024

CG-DME-51

External Insulin Pumps

Conversion new

1/3/2024

*CG-DME-52

Continuous Passive Motion Devices in the Home Setting

New

1/3/2024

CG-LAB-25

Outpatient Glycated Hemoglobin and Protein Testing

Revised

1/3/2024

CG-MED-92

Foot Care Services

Revised

1/3/2024

*CG-MED-94

Vestibular Function Testing

New

1/3/2024

*CG-SURG-09

Temporomandibular Disorders

Revised

12/28/2023

*CG-SURG-70

Gastric Electrical Stimulation

Revised

1/3/2024

CG-SURG-94

Keratoprosthesis

Revised

12/28/2023

CG-SURG-95

Sacral Nerve Stimulation and Percutaneous or Implantable Tibial Nerve Stimulation for Urinary and Fecal Incontinence, Urinary Retention

Revised

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CR-056176-24-CPN54635

Medical Policy & Clinical GuidelinesMedicaid Managed CareJune 5, 2024

Medical Policies and Clinical Utilization Management Guidelines Update

Effective July 7, 2024

The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third-Party Criteria below were developed or revised during Q4 2023. Note, several policies and guidelines were revised to provide clarification only and are not included. Some may have expanded rationales, medical necessity indications, or criteria and some may involve changes to policy position statements that might result in services that previously were covered being found to be not medically necessary.

Please share this notice with other providers in your practice and office staff.

To view a guideline, visit providers.anthem.com/oh.

Notes/Updates:

Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive:

  • CG-MED-94 — Vestibular Function Testing:
    • Outlines the Medically Necessary and Not Medically Necessary criteria for vestibular function testing.
  • CG-SURG-70 — Gastric Electrical Stimulation:
    • Added Medically Necessary and Not Medically Necessary criteria to Clinical Indications for removal, revision, or replacement of a gastric electrical stimulator.

Medical Policies

On November 9, 2023, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Anthem. These Medical Policies take effect July 7, 2024.

Publish date

Medical Policy number

Medical Policy title

New or revised

1/3/2024

LAB.00026

Systems Pathology and Multimodal Artificial Intelligence Testing for Prostate Cancer

Previously titled: Systems Pathology Testing for Prostate Cancer

Revised

1/3/2024

LAB.00050

Metagenomic Sequencing for Infectious Disease in the Outpatient Setting

Conversion New

12/28/2023

SURG.00158

Implantable Peripheral Nerve Stimulation Devices as a Treatment for Pain

Reviewed

Clinical UM Guidelines

On November 9, 2023, the MPTAC approved the following Clinical UM Guidelines applicable to Anthem. These guidelines were adopted by the medical operations committee for Medicaid members on January 4, 2024. These guidelines take effect July 7, 2024.

Publish date

Clinical UM Guideline number

Clinical UM Guideline title

New or revised

1/3/2024

CG-LAB-25

Outpatient Glycated Hemoglobin and Protein Testing

Revised

1/3/2024

CG-MED-92

Foot Care Services

Revised

1/3/2024

*CG-MED-94

Vestibular Function Testing

New

12/28/2023

*CG-SURG-70

Gastric Electrical Stimulation

Revised

1/3/2024

CG-SURG-94

Keratoprosthesis

Revised

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CD-057306-24

Prior AuthorizationCommercialJune 19, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Carelon Medical Benefits Management, Inc. genetic testing code updates

Effective for dates of service on and after September 1, 2024, the following codes will require prior authorization through Carelon Medical Benefits Management, Inc.

CPT® code

Description

81457

Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability

81458

Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, copy number variants and microsatellite instability

81459

Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements

81462

Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements

81463

Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability

81464

Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements

0420U

Oncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma

0422U

Oncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate

0423U

Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition

0424U

Oncology (prostate), exosome-based analysis of 53 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer

0425U

Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis, each comparator genome (eg, parents, siblings)

0426U

Genome (eg, unexplained constitutional or heritable disorder or syndrome), ultra-rapid sequence analysis

0428U

Oncology (breast), targeted hybrid-capture genomic sequence analysis panel, circulating tumor DNA (ctDNA) analysis of 56 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutation burden

0434U

Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes

0438U

Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene-drug interactions

As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management in one of several ways:

  • Access the ProviderPortalSM for Carelon Medical Benefits Management directly at providerportal.com.
  • Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
  • Access Availity.com.

If you have any questions related to guidelines, please contact Carelon via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines here.

Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-059592-24-CPN59056

Prior AuthorizationMedicaid Managed CareJune 20, 2024

Prior authorization requirement changes effective August 1, 2024

Effective August 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medicaid members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines (including definitions and specific contract provisions/exclusions), take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims.

Prior authorization requirements will be added for the following code(s):

Code

Description

C9790

Histotripsy (for example, nonthermal ablation via acoustic energy delivery) of malignant renal tissue, including image guidance

To request PA, you may use one of the following methods:

  • Web: Once logged in to Availity Essentials at Availity.com.
  • Fax: 877-643-0672
  • Phone: 800-601-9935

Not all PA requirements are listed here. Detailed PA requirements are available to care providers on providers.anthem.com/oh on the Resources tab or for contracted care providers by accessing Availity.com. Care providers may also call Provider Services at 844-912-1226 for assistance with PA requirements.

UM AROW A2023M0967

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CD-050784-24-CPN50146

Prior AuthorizationMedicaid Managed CareJune 11, 2024

Prior authorization requirement changes

Effective August 1, 2024

Effective August 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medicaid members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines (including definitions and specific contract provisions/exclusions), take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. 

Prior authorization requirements will be added for the following code(s):

Code

Description

81173

AR (androgen receptor) (such as, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence

81247

G6PD (glucose-6-phosphate dehydrogenase) (such as, hemolytic anemia, jaundice), gene analysis; common variant(s) (such as, A, A-)

81249

G6PD (glucose-6-phosphate dehydrogenase) (such as, hemolytic anemia, jaundice), gene analysis; full gene sequence

81307

PALB2 (partner and localizer of BRCA2) (such as, breast and pancreatic cancer) gene analysis; full gene sequence

81336

SMN1 (survival of motor neuron 1, telomeric) (such as, spinal muscular atrophy) gene analysis; full gene sequence

81403

Molecular pathology procedure, Level 4 (such as, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons):

EPCAM (epithelial cell adhesion molecule) (such as, Lynch syndrome), duplication/deletion analysis.

81405

Molecular pathology procedure, Level 6 (such as, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, (such as targeted cytogenomic array analysis) [when specified as the following]:

ARSA (arylsulfatase A) (such as, arylsulfatase A deficiency), full gene sequence
BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (such as, maple syrup urine disease, type 1A), full gene sequence
DBT (dihydrolipoamide branched chain transacylase E2) (such as, maple syrup urine disease type 2), duplication/deletion analysis
DHCR7 (7-dehydrocholesterol reductase) (such as, Smith-Lemli-Opitz syndrome), full gene sequence
GLA (galactosidase, alpha) (such as, Fabry disease), full gene sequence
NLGN3 (neuroligin 3) (such as, autism spectrum disorders), full gene sequence;
NLGN4X (neuroligin 4, X-linked) (such as, autism spectrum disorders), full gene sequence
OTC (ornithine carbamoyltransferase) (such as, ornithine transcarbamylase deficiency), full gene sequence
TGFBR1 (transforming growth factor, beta receptor 1) (such as, Marfan syndrome), full gene sequence
TGFBR2 (transforming growth factor, beta receptor 2) (such as, Marfan syndrome), full gene sequence

81440

Nuclear encoded mitochondrial genes (such as, neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP

To request PA, you may use one of the following methods:

  • Web: Once logged in to Availity Essentials at Availity.com.
  • Fax:
    • Physical health: 877-643-0672
    • Behavioral health: 866-577-2183
  • Phone: 800-601-3395

Not all PA requirements are listed here. Detailed PA requirements are available to providers on providers.anthem.com/oh on the Resources tab or for contracted providers by accessing Availity.com. Providers may also call Provider Services at 844-912-1226 for assistance with PA requirements.

UM AROW A2024M1371

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

OHBCBS-CD-058688-24-CPN57596

Reimbursement PoliciesCommercialJuly 1, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Reimbursement policy update: Incident to Services — Professional

Beginning with dates of service on or after October 1, 2024, Anthem will update the Incident to Service — Professional policy. The intent of the policy is to identify the reimbursement guidelines for incident to services.

This reimbursement policy identifies the following two different types of incidents:

  • Incident to Billing: When Incident to billing services are rendered and billed in accordance with this policy, the incident to services are eligible for reimbursement based on a 15% reduction of the maximum allowance of the applicable supervising provider’s fee schedule.
  • Incident to Services or Supplies: Incident to services or supplies that are essential to the performance of professional service are considered bundled in the primary service and are not allowed for separate reimbursement.

The Related Coding section of the policy includes Modifier SA which must be appended when the supervising physician is billing on behalf of non-physician practitioner (NPP) for non-surgical services.

The policy has been renamed to Incident to Services and Billing — Professional to define incident to services from incident to billing guidelines.

For specific policy details, visit the reimbursement policy page at Anthem.com/provider.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-061323-24-CPN61066

Reimbursement PoliciesCommercialJuly 1, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Reimbursement policy update: Frequency Editing — Professional

Beginning with dates of service on or after October 1, 2024, Anthem will update the Related Coding section of the Frequency Editing — Professional reimbursement policy.

This policy identifies reimbursement for a procedure or service that is billed for a single member, on a single date of service by the same provider and/or provider group, up to the maximum number of units allowed. In addition to using claims processing logic to determine when the use of multiple units is appropriate, we use the nomenclature for a particular CPT® or HCPCS level II code, the CMS’s medically unlikely edits (MUEs) designation, industry standards, or the ability to clinically perform or report a specific service more than one time on a single date of service or within a specific date span per member, per provider in making these determinations.

In the Related Coding section of the policy, the following updates will be made:

CPT maximum frequency code list:

  • Remove 36415 and 36416 (refer to laboratory and venipuncture C-10001)
  • Remove 96158-96159, 96164-96165 (refer to health and behavioral assessment/intervention C-11003)
  • Delete 76942, 77002, 77003, 77012, 77021, 77338, 77600, 77605, 80320-80377, 81479, 86160, 87483, 87491, 87591, 88305, 87529, 90378, 92250, 92273, 92274, 92326, 93325, 95925, 95926, 95938, 95927, 95928, 95929, 95939, 96900, 97012, 97016, 97018, 97022, 97024, 97026, 97028, 93792, and 93793

HCPCS maximum frequency code list:

  • Remove S9529 (refer to laboratory and venipuncture C-10001)
  • Remove G0480, G0481, G0482, and G0483 (refer to drug screen testing — professional C-12004)
  • Remove C9257, G0480, G0481, G0482, and G0483
  • Add A4238, A4239, A6520-A6529, A6552-A6589, A6593-A6610, and Q0509

For specific policy details, visit the reimbursement policy page at anthem.com/provider.

Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-061232-24

Reimbursement PoliciesCommercialJuly 1, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

New reimbursement policy: Diagnostic Radiopharmaceuticals and Contrast Materials — Professional and Facility

Beginning with dates of service on or after October 1, 2024, Anthem will implement a new reimbursement policy titled Diagnostic Radiopharmaceuticals and Contrast Materials —Professional and Facility.

Under this policy, when radiopharmaceuticals and contrast materials are billed by the facility, such services are not reimbursed as they are considered included in the facility fee. In addition, the following statement was removed from the Place of Service — Professional reimbursement policy and added to this policy:

The health plan does not allow separate reimbursement for diagnostic radiopharmaceutical and contrast materials by professional providers when reported in a facility place of service.

The Related Coding section contains specific codes with guidelines for both professional and facility providers.

For specific policy details, visit the reimbursement policy page at anthem.com/provider.

Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-061235-24

Federal Employee Program (FEP)CommercialJuly 1, 2024

Antidepressant Medication Management (AMM)

The National Committee Quality Assurance (NCQA) develops and collects HEDIS® measurements to set performance and drive improvement in quality-of-care outcomes.

The Federal Employee Program® (FEP) for Anthem is continuously working to improve clinical quality of care and performance outcomes. To comply with the NCQA standards and improve HEDIS AMM performance rate, FEP takes this opportunity to remind providers to document every service rendered in an accurate, timely manner and use the appropriate ICD-10-CM, CPT®, and HCPCS codes when billing services rendered for patients who are receiving antidepressant medications. Below is a description of the AMM measure, why it is important, exclusions, and helpful tips (such as medical records documentation and best practices).

HEDIS AMM measure description

This HEDIS measure evaluates the percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment. Two rates are reported:

  • Effective acute phase treatment: the percentage of members who remained on antidepressant medication for at least 85 days (12 weeks)
  • Effective continuation phase treatment: the percentage of members who remained on an antidepressant medication for at least 180 days (6 months)

Members with any diagnosis of major depression who are seen in any of the care settings are included in the AMM measure.

Place of services

  • Outpatient visit
  • Telehealth visit
  • ED visit
  • Acute or nonacute inpatient stay
  • Intensive outpatient encounter or partial hospitalization
  • Community mental health center
  • E-Visit or virtual check-in (online assessment)

Why is the HEDIS AMM measure important?

Major depression is a serious mental illness with a significant burden of symptoms and the most common psychiatric disorder in individuals who die from suicide.1 Integrating the right antidepressant medication with appropriate behavioral therapy leads to positive benefits and outcomes for members. Compliance with antidepressant medication is an essential component in treatment guidelines for major depression.2

Exclusions

Enrollees who did not have an encounter with a diagnosis of major depression during the 121-day period from 60 days prior to the index prescription start date (IPSD) through the IPSD and the 60 days after the IPSD

Common behavioral health codes used with any diagnosis of major depression that trigger patients into the HEDIS AMM measure are:

Description

Behavioral health codes (ICD-10-CM, CPT, HCPCS, POS)

Major depression

ICD-10-CM: F32.0–F32.4, F32.9, F33.0–F33.3, F33.41, F33.42, F33.9. F34.1

BH outpatient visit

CPT: 98960–98962, 99078, 99202–99205, 99211–99215, 99242–99245,
99341–99345, 99347–99350, 99381–99387, 99391–99397, 99401–99404, 99411, 99412, 99483, 99492–99494, 99510

HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013 - H2020, T1015

Place of service (POS)

POS: 02, 10, 52, 53

Telehealth visit

POS: 10

CPT: 98966–98968, 99441–99443

ED visit

CPT: 99281–99285

E-visit or virtual check-in (online assessment)

CPT: 98970–98972, 98980, 98981, 99421–99423, 99457, 99458

HCPCS: G0071, G2010, G2012, G2250, G2251, G2252

Helpful tips

Medical record documentation:

  • Diagnosis of major depression
  • Date of services
  • Date of dispensing
  • Evidence of antidepressant medication prescription

Best practices:

  • Educate members that most antidepressants take four to six weeks to work.
  • Encourage members to continue any prescribed medication even if they feel better. Inform them of the danger of discontinuing suddenly. If they take the medication for less than six months, they are at a higher risk of recurrence.
  • Assess members within 30 days from when the prescription is first filled for any side effects and their response to treatment.
  • When patients are making a follow-up visit, educate and encourage patients to bring their discharge instructions and medications list to their first appointment.
  • Coordinate care between behavioral health and primary care physicians by sharing progress notes and updates.
  • Educate members on what to do in an emergency, such as when having suicidal thoughts.
  • Focus on member preferences for treatment, allowing the member to take ownership of their health and treatment plan.

  1. https://pubmed.ncbi.nlm.nih.gov/23411024: Accessed January 21, 2020.
  2. https://ncqa.org/hedis/measures/antidepressant-medication-management

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-060942-24

PharmacyMedicare AdvantageJune 20, 2024

Anthem expands specialty pharmacy precertification list

Effective for dates of service on and after October 1, 2024, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process.

Federal and state law, as well as state contract language and CMS guidelines (including definitions and specific contract provisions/exclusions), take precedence over these precertification rules. They must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.

HCPCS codes

Medicare Part B drugs

J3490, J3590

Amtagvi (lifleucel)

J3490, J3590

iDoseTR (travoprost implant)

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CR-058746-24-CPN58434

PharmacyCommercialJuly 1, 2024

Notice of Material Amendments to Contract and/or Change to Prior Authorization Requirements

Correction: Specialty pharmacy updates — July 2024

This article was updated on October 9, 2024, to remove Ilumya as non-preferred from the step therapy requirements section below. Ilumya is not being added to the step therapy program at this time.

Specialty pharmacy updates for Anthem are listed below.

Anthem’s medical specialty drug review team manages prior authorization (PA) clinical review of non-oncology use of specialty pharmacy drugs. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc., a separate company.

Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request PA review for your patients’ continued use of these medications.

Inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.

Prior authorization updates

Effective for dates of service on or after October 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our PA review process.

Access our Clinical Criteria to view the complete information for these prior authorization updates.

Clinical Criteria

Drug

HCPCS or CPT® Code(s)

CC-0003*

Alyglo (immune globulin intravenous, human-stwk)

J1599

CC-0062

Simlandi (adalimumab-ryvk)

J3590

CC-0261

Winrevair (sotatercept-csrk)

C9399, J3590

* Oncology use is managed by Carelon Medical Benefits Management.

Note: PA requests for certain medications may require additional documentation to determine medical necessity.

Step therapy updates

Effective for dates of service on or after October 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our existing specialty pharmacy medical step therapy review process.

Access our Clinical Criteria to view the complete information for these step therapy updates.

Clinical Criteria

Status

Drug

HCPCS or CPT Code(s)

CC-0003

Non-preferred

Alyglo (immune globulin intravenous, human-stwk)

J1599

CC-0062

Non-preferred

Cimzia (certolizumab pegol)

J0717

CC-0042

Non-preferred

Cosentyx intravenous (secukinumab)

C9399, J3490, J3590, C9166

CC-0050

Non-preferred

Omvoh (mirkizumab-mrkz)

C9168, J3590

Quantity limit updates

Effective for dates of service on or after October 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our quantity limit review process.

Access our Clinical Criteria to view the complete information for these quantity limit updates.

Clinical Criteria

Drug

HCPCS or CPT Code(s)

CC-0062

Simlandi (adalimumab-ryvk)

J3590

CC-0261

Winrevair (sotatercept-csrk)

C9399, J3590

Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CM-060687-24-CPN60563, MULTI-BCBS-CM-069897-24

Quality ManagementMedicare AdvantageJuly 1, 2024

Understanding your role in the Health Outcomes Survey

The Centers for Medicare & Medicaid Services (CMS) Health Outcomes Survey (HOS) gathers patient-reported health outcomes from members enrolled in Medicare Advantage plans to support quality improvement activities and improve the overall health of members.

Increased awareness of all HOS measures can help guide your provider interactions with your patients and positively impact HOS results and can help impact your Star rating.

Refer to attachment to view full details

Anthem Blue Cross and Blue Shield is the trade name of Community Insurance Company. Independent licensee(s) of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

MULTI-BCBS-CR-055932-24-CPN55629

ATTACHMENTS (available on web): Understanding your role in the Health Outcomes Survey (pdf - 0.88mb)